Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters











Database
Language
Publication year range
1.
J Pediatr ; 131(4): 598-602, 1997 Oct.
Article in English | MEDLINE | ID: mdl-9386666

ABSTRACT

OBJECTIVE: As more children survive acute lymphoblastic leukemia (ALL), questions are raised regarding how the disease and its therapy affect their pubertal development. STUDY DESIGN: The National Institute of Child Health and Human Development-National Cancer Institute-Children's Cancer Group Leukemia Follow-Up Study used a historical cohort design to investigate menarche in 188 ALL survivors who were premanarchal at diagnosis, aged at least 18 years, at least 2 years after diagnosis, alive, and in remission. Female siblings of ALL survivors (n = 218) served as control subjects. RESULTS: Menarche occurred within the normal age range in 92% of survivors and 96% of the control subjects (p = 0.09). Early menarche occurred in four survivors (2%) and three control subjects (1%). Delayed, absent, or medically induced menarche was reported by 12 survivors (6%) and six control subjects (3%). Compared with the control subjects, survivors of ALL who received 1800 cGy cranial radiation before the age of 8 years had significantly earlier menarche, relative hazard (RH) of 2.2 (95% confidence interval: 1.4, 3.4 [p = 0.0003]). Survivors receiving 2400 cGy of craniospinal radiation with or without abdominal radiation had significantly later menarche than the control subjects, RH 0.4 (95% confidence interval: 0.3, 0.7 [p = 0.0002]). CONCLUSIONS: In this large cohort of ALL survivors, the risk of disordered menarche was low. However, younger subjects receiving 1800 cGy cranial radiation and those receiving 2400 cGy below the diaphragm required careful monitoring.


Subject(s)
Menarche/radiation effects , Precursor Cell Lymphoblastic Leukemia-Lymphoma/radiotherapy , Survivors , Adolescent , Child , Cohort Studies , Dose-Response Relationship, Radiation , Female , Humans
2.
J Pediatr ; 131(1 Pt 2): S37-41, 1997 Jul.
Article in English | MEDLINE | ID: mdl-9255226

ABSTRACT

Long-term survival in children with cancer has increased markedly in the past 15 years. However, impaired linear growth and thyroid dysfunction that vary according to the age at diagnosis and treatment and to the dose and duration of radiation and chemotherapy have been described in these patients. The impact of cranial irradiation on the hypothalamic-pituitary-adrenal axis and on pubertal maturation has been less well studied. A positive correlation between the age at diagnosis and the age at onset of puberty in children who have been treated with high-dose cranial radiation therapy for central nervous system (CNS) tumors has been found recently. Frank adrenal insufficiency is uncommon after high-dose CNS irradiation, but alterations in the hypothalamic-pituitary-adrenal axis do occur. Assessments of the effects of newer modes of radiation therapy such as hyperfractionated craniospinal radiation suggest a lower incidence of primary hypothyroidism in the long term.


Subject(s)
Central Nervous System Neoplasms/radiotherapy , Cranial Irradiation , Hypothalamo-Hypophyseal System/radiation effects , Pituitary-Adrenal System/radiation effects , Puberty/radiation effects , Radiation Injuries/etiology , Adolescent , Adrenal Insufficiency/etiology , Age Factors , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/therapeutic use , Central Nervous System Neoplasms/drug therapy , Child , Female , Growth Disorders/etiology , Humans , Hypothalamo-Hypophyseal System/drug effects , Hypothyroidism/etiology , Incidence , Male , Pituitary-Adrenal System/drug effects , Puberty/drug effects , Puberty, Precocious/etiology , Radiotherapy Dosage , Survival Rate , Thyroid Diseases/etiology , Time Factors
3.
J Pediatr ; 130(2): 210-6, 1997 Feb.
Article in English | MEDLINE | ID: mdl-9042122

ABSTRACT

OBJECTIVE: To examine the impact of bone marrow transplantation (BMT), using high-dose chemotherapy and hyperfractionated total body irradiation, on gonadal function in survivors of acute leukemia treated during childhood. STUDY DESIGN: We conducted a retrospective study of 33 subjects (17 boys) who underwent a BMT for acute leukemia (acute lymphoblastic leukemia, n = 20; acute myelogenous leukemia, n = 13) at a single institution. All patients were prepubertal at the time of BMT (median age, 7.1 years (3.7 to 11.6 years)); at the time of their last examination the boys were a median of 14 years (10.4 to 17.1 years) of age and the girls were a median of 16.9 years (9.5 to 21.9 years) of age. RESULTS: Of 17 boys, 14 (82%) entered puberty spontaneously and 13 demonstrated age-appropriate plasma concentrations of testosterone. Two boys (aged 10.5 and 11 years) remain clinically and hormonally prepubertal, and one boy has overt Leydig cell failure requiring androgen replacement therapy. Thirty-six percent of pubertal boys have elevated plasma concentrations of luteinizing hormone and 64% have raised levels of follicle-stimulating hormone. Boys with increased levels of luteinizing hormone were significantly younger at BMT (5.4 +/- 0.8 vs 7.8 +/- 0.8 years; p = 0.024). Of 16 girls, 9 (56%) had spontaneous puberty with onset of menarche at a median age of 13 years (9.5 to 15.8 years). Though six (67%) of these nine girls have had increased plasma concentrations of luteinizing and follicle-stimulating hormones, normalization has occurred in two during a period of 4 to 7 years. The remaining seven subjects required hormone replacement because of clinical and biochemical evidence of ovarian failure. One of these subjects has recovered ovarian function after 5 1/2 years. Female patients with ovarian failure were significantly older at BMT compared with female patients with spontaneous puberty/menarche (8.6 +/- 23 years vs 6.1 +/- 1.8; p = 0.03). CONCLUSION: Our results indicate that most prepubertal boys undergoing BMT with chemotherapy and hyperfractionated total body irradiation can expect to enter and progress normally through puberty. For prepubertal girls treated with these regimens, at least 50% retain adequate ovarian function to enter puberty and menstruate regularly.


Subject(s)
Bone Marrow Transplantation/adverse effects , Leukemia, Myeloid, Acute/therapy , Ovary/physiology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy , Testis/physiology , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Bone Marrow Transplantation/methods , Child , Child, Preschool , Combined Modality Therapy , Female , Follow-Up Studies , Humans , Infant , Leukemia, Myeloid, Acute/physiopathology , Male , Ovary/drug effects , Ovary/radiation effects , Precursor Cell Lymphoblastic Leukemia-Lymphoma/physiopathology , Puberty/drug effects , Puberty/radiation effects , Retrospective Studies , Testis/drug effects , Testis/radiation effects , Whole-Body Irradiation/adverse effects
4.
J Pediatr ; 123(1): 59-64, 1993 Jul.
Article in English | MEDLINE | ID: mdl-8320626

ABSTRACT

We analyzed growth and final heights in 127 patients (68 female patients) treated for childhood acute lymphoblastic leukemia. Central nervous system prophylaxis included either no cranial radiation therapy (CRT) (n = 38), irradiation with 1800 centigrays (cGy) (n = 36), or irradiation with 2400 cGy (n = 53). None of the patients received spinal irradiation. Mean (+/- SEM) age at diagnosis was 6.4 +/- 0.25 years, mean height standard deviation score (SDS) at diagnosis was 0.28 +/- 0.12, and mean age at final height was 18.26 +/- 0.19 years. The change in height SDS between diagnosis and achievement of final height was significant for all treatment groups: -0.49 +/- 0.14, no CRT; -0.65 +/- 0.15, 1800 cGy; and -1.38 +/- 0.16, 2400 cGy. Irradiated patients had a greater loss in height SDS compared with the nonirradiated patients (p < 0.01), and those treated with 2400 cGy CRT had a greater decrease in final height SDS than the patients treated with 1800 cGy (p < 0.01). Both younger age and female sex were significantly associated with a greater decrease in height SDS in the patients treated with CRT; girls < or = 4 years of age at diagnosis had a mean loss in height SDS that was more than twice that observed for others treated with the same dose of CRT. Thus, although modern regimens for acute lymphoblastic leukemia (no CRT or 1800 cGy CRT) appear overall to have only a modest impact on final height, patients, especially girls, treated with 1800 cGy CRT at a young age remain at risk for clinically significant growth failure.


Subject(s)
Body Height/radiation effects , Cranial Irradiation , Precursor Cell Lymphoblastic Leukemia-Lymphoma/radiotherapy , Age Factors , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Child , Child, Preschool , Combined Modality Therapy , Female , Growth/radiation effects , Humans , Logistic Models , Male , Michigan/epidemiology , Minnesota/epidemiology , Philadelphia/epidemiology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma/epidemiology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/physiopathology , Radiotherapy Dosage , Retrospective Studies , Sex Factors
5.
J Pediatr ; 105(2): 223-7, 1984 Aug.
Article in English | MEDLINE | ID: mdl-6747754

ABSTRACT

Thyroid function was measured serially in 28 children with Hodgkin disease diagnosed from 1971 to 1978. The patients' ages ranged from 4 to 16 years at diagnosis, and treatment consisted of chemotherapy only (four patients), radiation alone (15), or radiation plus chemotherapy (nine). None of the four children given chemotherapy only developed thyroid hypofunction, in contrast to 21 (88%) of the 24 children given high doses of radiation (P less than 0.001). Thyroid function in three patients with compensated hypothyroidism and in one child with primary hypothyroidism reverted to normal without thyroid replacement. One child given chemotherapy only and one child given radiation only became transiently hyperthyroid. These results indicate that patients given combined modality therapy for Hodgkin disease are at high risk for thyroid abnormalities. The results of long-term follow-up of thyroid function demonstrate, however, that all such thyroid abnormalities may not necessarily be permanent.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Hodgkin Disease/therapy , Hypothyroidism/etiology , Radiotherapy/adverse effects , Adolescent , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Child , Child, Preschool , Combined Modality Therapy , Female , Follow-Up Studies , Humans , Male , Thyroid Function Tests , Thyrotropin/blood , Thyroxine/blood
SELECTION OF CITATIONS
SEARCH DETAIL